Melatonin: Endogenous Production, Dose, and What Evidence Actually Supports

Two common stories circulate about melatonin supplements. One says the hormone is harmless because the body already makes it. The other says taking a pill will teach the pineal gland to quit and leave you dependent on a bottle. Neither story is a complete account of the pharmacology.

Current human evidence does not support the claim that ordinary melatonin use permanently shuts down the body's own production. Studies that measured endogenous markers after months of treatment found preserved secretion and no clear withdrawal syndrome or rebound insomnia in the populations studied.[1][3] An older, small case series in a specific psychiatric population at a high dose raised the possibility of suppression in some patients.[2] That is a reason for nuance, not a reason to tell most adults that melatonin predictably disables pineal function.

The intuition behind the fear is understandable. Several endocrine systems reduce their own output when an external hormone is supplied. Melatonin production, though, is driven largely by the circadian system and by light: levels rise in darkness before habitual sleep, peak in the biological night, and fall toward morning. Exogenous melatonin can shift circadian timing depending on when it is taken, and blood levels can exceed physiologic concentrations depending on dose. That still does not prove permanent loss of pineal secretory capacity. Analogies to corticosteroids or testosterone transfer vocabulary more reliably than regulatory architecture.

Measurement is awkward while someone is still taking melatonin, because the exogenous molecule is chemically identical to the endogenous one. More informative designs look at endogenous markers after the supplement stops, often using urinary 6-sulfatoxymelatonin.

What usually matters clinically is not whether the pineal will become lazy. It is whether melatonin is the right tool, at the right time, at a physiologic-leaning dose. Melatonin is primarily a circadian signal. It has a defensible role in selected circadian rhythm disorders and related situations. The American Academy of Sleep Medicine pharmacologic guideline suggested against melatonin for chronic sleep-onset or sleep-maintenance insomnia in adults because the evidence for clinically meaningful benefit was weak.[4] If the real problem is untreated apnea, conditioned insomnia, restless legs, alcohol-related fragmentation, pain, or a perimenopausal maintenance pattern, raising the melatonin dose escalates the wrong answer.

Dose guidance for this knowledge base: for most adults, keep melatonin at 1 mg or less when it is used at all. Timing relative to the desired phase shift usually matters more than pushing milligrams higher. Larger doses can increase next-day drowsiness, vivid dreams, headache, or dizziness without improving circadian effect.

Commercial products are not laboratory standards. Analyses of marketed melatonin supplements have found large gaps between labeled and measured content, lot-to-lot variation, and occasional unexpected compounds such as serotonin.[5] A person who believes they take 3 mg may be taking something substantially different. Prefer the lowest effective dose, a consistent timing plan under clinician guidance when treating a circadian disorder, and skepticism toward megadose marketing.

Medications for sleep problems are usually short-term. When medication is used longer, it is most often treating a condition other than primary insomnia. Melatonin for circadian indication should follow the same discipline: clear indication, defined duration, and follow-up rather than indefinite nightly use "just in case."